Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pulmonary embolism and bradycardia in a NSCLC patient treated with crizotinib for a rare mutation.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Jan 2023

Shi Yunjing, Qiu Zeping, Ding Yongjie, Chen Yanjia, Zhang Andi, Jin Wei

Abstract excerpt

INTRODUCTION: Lung cancer is a major global health problem because of its high incidence and mortality. Targeted therapies have transformed treatment of driver-mutated metastatic non-small cell lung cancer (NSCLC). Nevertheless, recent studies demonstrated that cardiovascular disease (CVD) was the second leading cause of mortality in cancer survivors now, management of patients' cardiovascular health during the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Bradycardia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Crizotinib

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pulmonary Embolism

Source

Identifiers

PMID: 35466809
DOI: 10.1177/10781552221091595

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pulmonary embolism and bradycardia in a NSCLC patient treated with crizotinib for a rare mutation.PMID 35466809Read ↗

Pulmonary Embolism And Bradycardia in a NSCLC Patient Treated With Crizotinib For a Rare Mutation: A Case ReportSemantic proximity Read ↗

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.Semantic proximity Read ↗

Cardiotoxicity Associated with Targeted Therapies in Lung Cancer: A Retrospective Cohort Study of 2,427 Patients with FAERS Pharmacovigilance ValidationSemantic proximity Read ↗

Management of nonbacterial thrombotic endocarditis (NBTE) in advanced non-small cell lung cancer (NSCLC) patients with driver mutation: two case reports.Semantic proximity Read ↗

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read ↗

Cancer Therapeutics-Related Cardiac Dysfunction - Insights From Bench and Bedside of Onco-Cardiology.Semantic proximity Read ↗

Potentially fatal complications of systemic air embolism after computed tomography-guided transthoracic needle biopsy in lung cancer harboring epithelial growth factor receptor mutation: A case report.Semantic proximity Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.Semantic proximity Read ↗

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Semantic proximity Read ↗

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.